WO2004050848A2 - Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse - Google Patents

Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse Download PDF

Info

Publication number
WO2004050848A2
WO2004050848A2 PCT/US2003/038224 US0338224W WO2004050848A2 WO 2004050848 A2 WO2004050848 A2 WO 2004050848A2 US 0338224 W US0338224 W US 0338224W WO 2004050848 A2 WO2004050848 A2 WO 2004050848A2
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
solution
mpeg
wash solution
dextrose
Prior art date
Application number
PCT/US2003/038224
Other languages
English (en)
Other versions
WO2004050848A3 (fr
Inventor
Adonis Stassinopoulos
Basha Clark
Original Assignee
Cerus Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corporation filed Critical Cerus Corporation
Priority to AU2003302499A priority Critical patent/AU2003302499A1/en
Publication of WO2004050848A2 publication Critical patent/WO2004050848A2/fr
Publication of WO2004050848A3 publication Critical patent/WO2004050848A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés pour préparer une composition de globules rouges qui présente une antigénicité nettement réduite. Ces procédés consistent à optimiser des conditions de réaction pour lier des composés de masquage d'antigène aux globules rouges, sans modifier de manière importante le fonctionnement de ces globules rouges, ce qui permet notamment de réduire l'hémolyse des globules rouges résultant d'un traitement de ceux-ci. Les compositions de globules rouges sont notamment utilisées pour être administrées à un individu chez lequel le potentiel d'une réaction immunitaire est élevé, par exemple chez des receveurs de sang allo-immunisés ou dans des situations de trauma où la possibilité d'une transfusion d'unité de sang non appropriée est plus élevée. Les compositions de globules rouges selon cette invention permettent de réduire nettement le risque d'une réaction immunitaire associée à une transfusion.
PCT/US2003/038224 2002-12-04 2003-12-03 Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse WO2004050848A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003302499A AU2003302499A1 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US43121502P 2002-12-04 2002-12-04
US43121602P 2002-12-04 2002-12-04
US43121302P 2002-12-04 2002-12-04
US43121402P 2002-12-04 2002-12-04
US60/431,214 2002-12-04
US60/431,213 2002-12-04
US60/431,216 2002-12-04
US60/431,215 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050848A2 true WO2004050848A2 (fr) 2004-06-17
WO2004050848A3 WO2004050848A3 (fr) 2004-12-09

Family

ID=32475715

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/038224 WO2004050848A2 (fr) 2002-12-04 2003-12-03 Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse
PCT/US2003/038349 WO2004050897A2 (fr) 2002-12-04 2003-12-03 Procedes de preparation de globules rouges a masquage d'antigene et hemolyse reduite au moyen de serums
PCT/US2003/038262 WO2004050029A2 (fr) 2002-12-04 2003-12-03 Nouveaux composes de polyethylene glycol actives
PCT/US2003/038270 WO2004049914A2 (fr) 2002-12-04 2003-12-03 Procedes destines a faire reagir un compose de masquage d'antigenes avec des erythrocytes presentant une efficacite elevee

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/US2003/038349 WO2004050897A2 (fr) 2002-12-04 2003-12-03 Procedes de preparation de globules rouges a masquage d'antigene et hemolyse reduite au moyen de serums
PCT/US2003/038262 WO2004050029A2 (fr) 2002-12-04 2003-12-03 Nouveaux composes de polyethylene glycol actives
PCT/US2003/038270 WO2004049914A2 (fr) 2002-12-04 2003-12-03 Procedes destines a faire reagir un compose de masquage d'antigenes avec des erythrocytes presentant une efficacite elevee

Country Status (2)

Country Link
AU (4) AU2003293237A1 (fr)
WO (4) WO2004050848A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CN102108119A (zh) 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
WO2023172180A1 (fr) * 2022-03-07 2023-09-14 Icoat Medical Ab Nouvelle utilisation de molécules de peg-phospholipide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (fr) * 2000-05-31 2001-12-06 Cerus Corporation Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL292906A (fr) * 1962-10-30

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (fr) * 2000-05-31 2001-12-06 Cerus Corporation Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
AU2003293237A1 (en) 2004-06-23
WO2004050897A3 (fr) 2004-08-26
WO2004049914A3 (fr) 2005-02-24
AU2003297614A8 (en) 2004-06-23
WO2004050897A2 (fr) 2004-06-17
AU2003297614A1 (en) 2004-06-23
AU2003298827A1 (en) 2004-06-23
AU2003302499A8 (en) 2004-06-23
WO2004049914A2 (fr) 2004-06-17
AU2003302499A1 (en) 2004-06-23
AU2003298827A8 (en) 2004-06-23
WO2004050848A3 (fr) 2004-12-09
WO2004050029A3 (fr) 2004-10-21
AU2003293237A8 (en) 2004-06-23
WO2004050029A2 (fr) 2004-06-17

Similar Documents

Publication Publication Date Title
ES2541135T3 (es) Medio de suspensión de hematíes
Böhmig et al. Strategies to overcome the ABO barrier in kidney transplantation
Scott et al. Cellular camouflage: fooling the immune system with polymers
Garratty Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion
Garratty Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs
CA2320156A1 (fr) Cellule antigene reduite et ses utilisations
US20030207247A1 (en) Preparation of red blood cells having reduced immunogenicity
US5908624A (en) Antigenic modulation of cells
EP0901521B1 (fr) Modulation antigenique de cellules
US20020042043A1 (en) Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
WO2004050848A2 (fr) Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse
Harrison et al. Separation of haemopoietic cells for biochemical investigation. Preparation of erythroid and myeloid cells from human and laboratory-animal bone marrow and the separation of erythroblasts according to their state of maturation
Wang et al. Polymer-mediated immunocamouflage of red blood cells: effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells
US7521174B2 (en) Universal red blood cells, methods of preparing same, and uses thereof
Yura et al. Structural effect of galactose residue in synthetic glycoconjugates on interaction with rat hepatocytes
CA2272925A1 (fr) Methode pour convertir le type sanguin
Doucet et al. Modification of xenoantigens on porcine erythrocytes for xenotransfusion
US8007784B1 (en) Antigenic modulation of cells
WO1999000145A1 (fr) Modulation antigenique de particules virales
US20180345250A1 (en) Method for the purification of whole blood or a blood-derived product
Srubiski Modification of red cell antigenic characteristics via covalent modification with branched poly (ethylene glycol)
Fisher et al. Properties of poly (ethylene glycol)-conjugated red blood cells
JPS63252252A (ja) Ｂリンパ球分離材、分離方法および分離器
CA2116138C (fr) Methodes et compositions pour l'attenuation du rejet de xenogreffes medie par des anticorps chez des receveurs humains
Nacharaju et al. Generation of universal red blood cells: an evaluation of various approaches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP